Patients received ixabepilone ( 40 mg/m ( 2 ) as a 3-hour intravenous infusion every 3 weeks ) plus oral capecitabine ( 1000 mg/m ( 2 ) administered twice each day ) , or capecitabine alone ( 1250 mg/m ( 2 ) twice each day ) .